KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial.Dig Liver DisPMID 39562215无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease.Alzheimers DementPMID 39575854PMC118484192025-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of perampanel in patients with seizures associated with Lennox-Gastaut syndrome: A randomized trial.EpilepsiaPMID 39576191PMC118277172025-Feb0.98未发现恶性肿瘤人群证据。待处理
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.Clin Genitourin CancerPMID 39579409无 PMCID2025-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39581197无 PMCID2025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy.Int J Clin OncolPMID 39585516无 PMCID2025-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39602678无 PMCID2025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.Br J PsychiatryPMID 39618237无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Pharmacokinetic/Pharmacodynamic Modeling of Efficacy and Hypoglycemia Rate When Switching From Once-Daily Basal Insulin to Once-Weekly Insulin Icodec Without or With a One-Time Additional Dose in Insulin-Experienced Individuals With Type 2 Diabetes.Endocr PractPMID 39631663无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.Lancet Gastroenterol HepatolPMID 39637881无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.Clin Genitourin Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39642775无 PMCID2025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.Int J UrolPMID 39648954无 PMCID2025-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy of CycloMesh™+Ropivacaine in the treatment of uncomplicated inguinal hernia after the Lichtenstein procedure: Results of a prospective multicentric double-blind study.J Visc SurgPMID 39674692无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn's Disease.Adv TherPMID 39692838PMC117871672025-Feb0.98未发现恶性肿瘤人群证据。待处理
Reduction of postoperative pain and opioid consumption by VVZ-149, first-in-class analgesic molecule: A confirmatory phase 3 trial of laparoscopic colectomy.J Clin AnesthPMID 39705738无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cells.TransfusionPMID 39719927PMC118262922025-Feb0.98未发现恶性肿瘤人群证据。待处理
Lubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.Aliment Pharmacol TherPMID 39744921PMC117549392025-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of SHR8554 on postoperative pain in subjects with moderate to severe acute pain following orthopedic surgery: A multicenter, randomized, double-blind, dose-explored, active-controlled, phase II/III clinical trial.Pharmacol ResPMID 39755132无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Nonopioid vs opioid analgesics after impacted third-molar extractions: The Opioid Analgesic Reduction Study randomized clinical trial.J Am Dent AssocPMID 39755971无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial.Nat MedPMID 39762418无 PMCID2025-Feb0.90The record describes a randomized phase 2 trial with a primary endpoint of pathological complete response (pCR), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis. The publication types include 'Clinical Trial, Phase II' and 'Clinical Trial, Phase III', but the abstract explicitly states it is a 'phase 2, randomized trial' with results. Phase 3 trials are only warranted, not presented. Therefore, it fails the 'phase3_or_definitive' and 'time_to_event' criteria.待处理
Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.Nat MedPMID 39775042无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.StrokePMID 39781748无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer?Clin Oncol (R Coll Radiol)PMID 39799639无 PMCID2025-Feb0.90The record describes a quality assurance sub-study of a definitive oncology RCT (SCOPE2), but it does not report any survival, progression, recurrence, or other efficacy outcomes eligible for KM digitization.待处理
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.Lancet HaematolPMID 39799953无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.MaturitasPMID 39809112无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Population exposure-response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata.CPT Pharmacometrics Syst PharmacolPMID 39812118PMC118129362025-Feb0.98未发现恶性肿瘤人群证据。待处理
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.Lancet Diabetes EndocrinolPMID 39818225无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity.J Cachexia Sarcopenia MusclePMID 39825571PMC117885882025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE.Lancet HIVPMID 39832519PMC118905822025-Feb0.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.Nat Med已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:AI 判定为 other;Extended Data Fig. 1:AI 判定为 forest plot;Extended Data Fig. 2:AI 判定为 flow diagram。PMID 39838117PMC118357122025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.Nat MedPMID 39838118PMC118357352025-Feb0.85The record is a Phase III randomized trial of a drug intervention in oncology with an original primary result. However, it does not meet the specific inclusion requirement of having a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The reported primary endpoint is pathological complete response (pCR), which is not a time-to-event endpoint.待处理
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy.Mult Scler Relat DisordPMID 39847856无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial.Lancet OncolPMID 39848272无 PMCID2025-Feb0.95Eligible oncology human Phase III randomized trial with OS as primary endpoint and original results, but excluded because the intervention is a procedural (thermal ablation vs. surgical resection) and not a drug-containing regimen, as required.待处理
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.Gynecol OncolPMID 39854806PMC119299562025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.Lancet NeurolPMID 39862879无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.Lancet NeurolPMID 39862880无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Assessment of Reperfusion Efficacy of Altelyse Versus Actilyse in Patients with Acute Myocardial Infarction: A Phase 3, Randomized, Double-Blinded, Non-inferiority Clinical Trial.Clin Drug InvestigPMID 39873854无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.J InfectPMID 39874991无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B).Neuromuscul DisordPMID 39879732无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39884222无 PMCID2025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.Lancet Glob HealthPMID 39890232PMC117830362025-Feb0.98未发现恶性肿瘤人群证据。待处理
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER.JACC Heart FailPMID 39909641无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39914418无 PMCID2025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39914419无 PMCID2025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.Ann Rheum DisPMID 39919893无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.ESMO OpenPMID 39921934PMC118507552025-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial.Circ Cardiovasc IntervPMID 39965044无 PMCID2025-Feb0.98未发现恶性肿瘤人群证据。待处理
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.Clin Transl SciPMID 39980062PMC118422202025-Feb0.95The study is a Phase III randomized trial of imetelstat in myelodysplastic syndromes, but the report is a translational/safety analysis focused on proarrhythmic potential and QTc prolongation. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The primary outcome described is the concentration-QTc relationship, which is a safety endpoint.待处理
Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.J Cachexia Sarcopenia MusclePMID 39992021PMC118488632025-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.Eur Respir JPMID 39467609PMC117998832025-Feb0.98未发现恶性肿瘤人群证据。待处理